 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || anti CD19/CD22 CAR NK cells / Allife Medical Science and Technology
New P1 trial: Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma (clinicaltrials.gov) - Jan 31, 2019
P1, N=10, Not yet recruiting, Sponsor: Allife Medical Science and Technology Co., Ltd.